按药物类别、给药途径、分子类型、适应症、最终用户和分销管道分類的肿瘤药物市场 - 全球预测 2025-2032

预计到 2032 年，抗癌药物市场规模将成长至 3,864.1 亿美元，复合年增长率为 7.92%。

主要市场统计数据
基准年2024年	2100亿美元
预计2025年	2255.4亿美元
预测年份：2032年	3864.1亿美元
复合年增长率（%）	7.92%

对不断发展的癌症治疗领域进行简洁、基础性的定位，整合科学创新、交付方式以及对相关人员策略的影响

肿瘤学领域正处于曲折点，这得益于临床进展、医疗服务提供方式的转变以及供应链敏感性的提高。本介绍概述了推动开发商、投资者、临床医生和付款人决策的关键力量，为策略行动定下了基调。近年来，治疗方法创新已经超越了传统的细胞毒性药物，包括荷尔蒙疗法、不断扩大的免疫疗法和高选择性标靶药物。在化疗中，甲醇烷基化化合物和抗代谢物等药物仍然是许多方案的基石。在免疫疗法中，工程细胞平台正在扩展，包括 CAR T 细胞疗法和基于查核点阻断的全身免疫调节剂，例如 CTLA-4 和 PD-1/PD-L1。标靶治疗不断发展，包括单株抗体（包括嵌合体和人源化抗体）以及针对激酶和细胞週期调节剂的小分子抑制剂。

同时，对给药方式和给药方式的考量已成为策略差异化因素。静脉、皮下和肌肉注射剂与日益扩展的口服方案共存，优先考虑门诊患者的便利性。包括单株抗体和治疗性疫苗在内的生物製药的兴起伴随着强调生物有效性和细胞内靶向的小分子药物项目。适应症很复杂，从白血病和淋巴瘤等血液系统骨髓恶性肿瘤，到急性骨髓性白血病和慢性淋巴性白血病、何杰金氏病金癌和非何杰金氏病癌等亚型，以及乳癌、大肠直肠癌、肺癌和摄护腺癌等固体癌肿瘤。最终用户包括医院、专科诊所和研究机构，每个机构都需要独特的供应、报销和临床整合策略，通路涵盖医院药房、零售店和线上管道，影响药物的可及性和依从性。

本概述强调，成功的肿瘤学策略必须将科学创新与生产、监管参与和商业营运的实际规划相结合。以下章节将探讨转型变革、关税相关压力、基于细分市场的优先事项、区域差异化因素、竞争行动，以及领导者在日益复杂的治疗和商业说明中应对的实用建议。

评估推动下一代癌症治疗和护理模式的关键技术、监管和商业性转变

过去十年，癌症领域发生了翻天覆地的变化，重新定义了治疗标准、商业模式和投资重点。随着嵌合抗原受体T细胞疗法的成熟以及针对CTLA-4和PD-1/PD-L1路径的查核点抑制剂的扩展，免疫肿瘤学的快速发展改变了治疗模式。这些治疗方法不仅在先前难以治癒的疾病中取得了持久的疗效，也重塑了人们对长期疾病控制和合併用药策略的预期。同时，标靶治疗的开发也在加速，单株抗体（包括嵌合体和人源化抗体）与小分子抑制剂（例如蛋白酪氨酸激酶抑制剂和週期蛋白依赖型激酶抑制剂）相辅相成，因此能够精准标靶化致癌因子。

生技药品生产和复杂细胞疗法的供应链正在经历与临床进展同步的开发创新，包括复杂的低温运输物流、与专业合约开发和受託製造厂商的合作，以及对某些极具挑战性疗法的现场能力的需求。同时，随着医疗保健系统和患者寻求减轻医疗机构负担并提高依从性的门诊替代方案，口服给药正日益受到青睐。数位化疗法、远端监控和分散式临床试验模式使更广泛的患者参与和更快的数据收集成为可能，而真实世界证据计画也日益支持报销方案。

监管途径正在透过加速核准机制、增加对替代终点和核准后承诺的依赖来适应新兴科学。在商业性，付款方正在尝试基于结果和价值的基本契约，而製造商则面临着将定价与已证实的临床效用挂钩的压力。总而言之，这些转变迫使相关人员追求灵活的开发平台、有韧性的生产布局和全面的证据策略，以充分了解新兴肿瘤药物资产的治疗和经济价值。

到 2025 年的累积关税趋势及其与供应链、筹资策略和肿瘤学相关人员之间的获取动态的相互作用的综合分析

改变跨境贸易和关税的政策行动将对复杂的医药供应链产生重大影响，而2025年宣布或实施的关税变化的累积影响需要谨慎解读。关税压力可能表现为原料药、生技药品（例如一次性组件和细胞培养基）以及特种辅料的投入成本上升。为此，製造商可能会重新评估其供应商组合，并加快替代供应商和委託製造製造商的资格认证，以降低集中风险。因此，一些公司可能会采取部分在岸或近岸外包策略，以缓解关税引发的波动，但这些措施会带来资本和时间成本、监管重新认证要求以及潜在的产能限制。

面对采购成本的上升，医院、专科诊所和医院药局可以加强处方笺管理，优先选择具有明确治疗价值和采购弹性的药品。研究机构可能会因承担与关税相关的采购和营运成本上涨而出现预算错位，这可能会影响研究者主导研究的速度和范围。分销管道（包括线上药局和零售药局）可以透过重新协商供应商合约和调整库存策略来适应变化，以在保护净利率的同时维持患者可及性。

在研发方面，上游成本的上升可能会对研发预算造成压力，并可能改变那些治疗差异较小的后期研发产品的核准/未核准标准。同时，随着企业改变生产布局，监管机构可能会严格审查供应的连续性和品质保证。因此，相关人员应追求全面的供应链可视性、关税衝击情境规划，并积极主动地与供应商和监管机构沟通，以在不损害创新奖励的情况下，维持药物的可及性和临床的连续性。

详细的细分情报将治疗层级、给药方法、分子类型、临床适应症和管道行为与战略要务联繫起来

以细分市场主导的观点揭示了跨治疗层级、给药途径、分子类型、适应症、最终用户和分销管道的差异化商业机会和营运需求。按药物类别细分，虽然传统化疗在组合方案中仍然必不可少，烷化剂和抗代谢药物在某些方案中有用，但免疫疗法子类别（CAR-T 细胞疗法和查核点抑製剂）由于其个性化生产和长期疗效特征而具有独特的製造、临床和商业性方法。查核点抑制剂的子集，包括 CTLA-4 抑制剂和 PD-1/PD-L1 抑制剂，强调全身性免疫调节，并需要与持久反应指标相关的独特证据。同时，週期蛋白依赖型激酶抑制剂和蛋白酪氨酸激酶抑制剂等小分子类别具有独特的开发和交付优势。

静脉、皮下或肌肉注射疗法需要输液能力、训练有素的临床工作人员和强大的低温运输管理，而口服製剂则允许分散配药和依从性解决方案。考虑到分子类型，市场分为生技药品（如单株抗体和疫苗）和小分子，每种製剂都需要量身定制的製造生态系统和监管证据包。基于适应症的细分突出表明，白血病和淋巴瘤等骨髓恶性肿瘤（包括急性骨髓性白血病、慢性淋巴性白血病、何杰金氏淋巴瘤和非何杰金氏淋巴瘤等亚型）正在推动对细胞疗法和新型组合策略的重点需求，而乳癌、结直肠癌、肺癌和前列腺癌等固体癌正在推动广泛的人群水平筛检、生物标誌物开发和长期生存护理的考虑。终端使用者细分凸显了医院、研究机构和专科诊所之间不同的采购和采用动态。最后，分销管道（医院、线上和零售）的差异决定了治疗药物的库存、报销和获取方式，直接影响依从性和后续疗效。整合这些细分层面，有助于根据临床和商业实际情况，制定有针对性的产品组合优先排序、供应链设计和证据产生活动。

地理差异和可操作的区域情报，使监管现实、製造能力和付款人环境与准入策略保持一致

区域动态显着影响全球肿瘤生态系的发展重点、报销途径和可及性策略。在美洲，先进的临床基础设施、深入的付款人和商业性参与以及专注的生物製药投资正在推动高成本创新治疗方法的快速应用，特别是在骨髓恶性肿瘤和精准靶向适应症领域。该地区的监管和报销讨论越来越依赖现实世界的结果和基于价值的安排，这些影响着产品上市顺序和商业性准入计划。欧洲、中东和非洲的法规环境和付款人能力各不相同，因此打入市场策略也各不相同。虽然西方医疗保健系统通常强调卫生技术评估主导的评估和价格谈判，但中东和非洲地区面临基础设施和产能限制，这会影响复杂生技药品和细胞疗法的推出时间表。因此，製造商必须定制准入模式、本地伙伴关係和能力建设倡议，以解决特定国家/地区的报销和交付限制。亚太地区是一个充满活力的市场，拥有强大的生产能力、快速增长的临床试验数量以及不断发展的报销制度。该地区多个国家正在投资国内生技药品和小分子药物的生产，这为全球研发机构带来了竞争压力和合作机会。在所有地区，在地化的临床证据、与本地意见领袖的合作以及强大的供应链韧性对于持续推进产品上市和扩大患者可及性都至关重要，每个地区都需要製定符合其医疗保健体系架构和患者群体需求的定制监管和商业策略。

决定肿瘤学竞争优势的关键生物製药、生物技术和製造合作伙伴的策略行动和能力发展

肿瘤学公司的行为反映了其对科学机会和营运复杂性的广泛策略频谱。大型综合製药公司优先考虑产品组合多元化，在创新生物製药和细胞疗法与小专利权系列的逐步改进之间取得平衡，同时利用规模效应投资于生产能力和全球商业网络。开发型生技公司通常专注于作用机制和基于生物标记的患者选择驱动差异化的适应症，而开发细胞疗法的公司则专注于建立专业化生产能力和伙伴关係，以实现分散式交付。合约开发和受託製造公司正在扩展其能力，以应对生物製药和复杂的细胞疗法工作流程，使其成为寻求降低资本强度和加速产能推出的赞助商的重要合作伙伴。

这些公司类型的通用策略行动包括寻求策略联盟、授权合约和选择性併购，以填补能力差距，特别是在基因编辑、细胞治疗自动化和高级分析等领域。该公司还在投资证据生成平台，将临床试验数据与真实世界治疗结果相结合，以支持付款人谈判和基于价值的合约。在营运方面，公司正在增强供应链视觉性和双重采购策略，以减少受关税主导的成本波动影响，并确保温度敏感型生技药品的连续性。竞争差异化越来越依赖于展示长期临床效用、管理复杂物流以及提供符合不同付款人需求的可靠定价和存取计划的能力。

为高阶主管提供实用的优先建议，以增强其肿瘤学产品组合的供应连续性、证据产生和商业性准备

行业领导者必须采取一系列协同行动，将科学进步转化为永续的商业性和临床影响。首先，透过多方采购、库存优化和在可行的情况下策略性地在岸外包，优先考虑供应链的弹性，这可以减轻关税引发的成本衝击，并确保温敏性生技药品和细胞治疗产品的稳定性。其次，在开发早期纳入真实世界证据策略和健康经济终点，可以使临床开发与付款人证据预期一致，从而提高报销准备度并减少上市摩擦。第三，投资製造伙伴关係和模组化生产技术，特别是针对复杂生技药品和CAR-T平台，可加速规模化生产，同时控制资本支出。

第四，设计灵活的商业化模式，既能适应医院管理，又能适应门诊口服治疗，可以改善病患的用药管道，促进护理过渡。第五，建立结合诊断和治疗能力的策略联盟，可以加强生物标记主导的定位，实现有针对性的适应症。第六，采用数位化和分散式临床试验方法可以扩大患者招募，加快数据收集，并支持核准后证据的产生。第七，与付款人协商创新的合约安排，包括基本契约结果的合同，可以使价格与临床表现保持一致，并降低采用高成本疗法的风险。最后，促进研发、监管事务、製造和商业团队之间的跨职能合作，可以确保更快的决策週期和一致的打入市场策略。总之，这些建议为寻求保持创新同时克服成本压力和准入障碍的组织提供了切实可行的蓝图。

结合相关人员访谈、文献综合和数据三角测量的透明、多方法研究途径检验了肿瘤学的见解和假设

本研究整合了一手和二手研究，旨在提供严谨且检验的见解。一手研究包括对各种相关人员进行结构化访谈，包括临床研究人员、医院药剂师、相关人员、专科诊所主任以及生物製药公司和製造外包的高阶主管。进行这些访谈是为了从多个观点了解实务、采购行为和证据期望。二手研究包括对同行评审文献、监管指导文件、公开意见书、会议记录和技术白皮书的系统性回顾，以建立全面的依证。使用数据三角测量技术来协调不同资讯来源的见解，并在后续专家咨询中对研究结果进行交叉检验，以确保一致性并解决任何差异。

应用分段映射将治疗层级、给药途径、分子类型、适应症、最终用户和分销管道与观察到的采用模式和操作限制进行匹配。品质保证步骤包括方法同侪审查、来源可追溯性和敏感度分析，以确定高度不确定性的领域。这种方法有其限制：相关人员访谈反映的是当前的做法和看法，这些做法和看法可能会迅速变化，公共文献可能落后于快速发展的技术创新。为了解决这些局限性，本研究强调透明的假设和对关键结论的具体证据的引用，并鼓励用户透过与策略问题一致的有针对性的主要参与来补充这项工作。所有关键互动都适用道德标准和保密通讯协定，参与者共用的专有资讯按照商定的保密条款处理。

结论性综合强调了技术创新、营运准备和政策考虑的融合，这些将决定肿瘤学的长期影响

本文展现的科学创新、营运复杂性和政策动态的融合，凸显了肿瘤学相关人员必须既敏捷又谨慎。免疫疗法和标靶药物的进展展现出临床前景，但要实现规模化应用，需要製定涵盖生产弹性、证据生成和自适应商业化的整合策略。到2025年，关税和贸易发展将增加营运风险，这可能会影响投入成本、采购行为和取得途径，因此，供应链可视性和情境规划至关重要。

市场区隔和区域分析表明，治疗方法、交付和地理差异需要量身定制的方法，而不是一刀切的方案。投资于模组化製造、智慧伙伴关係和早期付款人参与的公司将更有能力应对报销的复杂性，并确保创新治疗方法的持久应用。同时，医疗系统和付款人将受益于更清晰的疗效数据和将成本与长期患者利益相结合的协作模式。最后，目前的环境有利于那些将科学严谨性与营运远见结合的组织。相关人员将最有能力将治疗方法突破转化为持续的临床和商业性成功。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 快速实施针对固体癌特异性突变的个人化新抗原疫苗平台
• 提高超灵敏液态生物检体检测的整合度，用于监测造血系统恶性肿瘤的微量残存疾病
• 将靶向 CD19 的 CAR-T 细胞疗法扩展至瀰漫大 B 细胞淋巴瘤的初始治疗通讯协定
• 新一代 KRAS G12C 和 G12D 抑制剂的出现，在肺癌和大肠直肠癌中表现出持久疗效
• 製药公司与诊断开发商扩大PD-L1伴随诊断联合开发案的合作

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：按药物类别分類的抗癌药物市场

• 化疗药物
  • 烷化剂
  • 抗代谢物
• 荷尔蒙疗法剂
• 免疫治疗药物
  • CAR-T细胞疗法
  • 查核点抑制剂
    • CTLA-4抑制剂
    • PD-1/PD-L1抑制剂
• 标靶治疗药物
  • 单株抗体
    • 嵌合体
    • 人性化
  • 小分子抑制剂
    • 週期蛋白依赖型激酶抑制剂
    • 蛋白酪氨酸激酶抑制剂

第九章 抗癌药物市场（依给药途径）

• 注射
  • 肌肉注射
  • 静脉
  • 皮下
• 口服

第 10 章 抗癌药物市场（依分子类型）

• 生物製药
  • 单株抗体
  • 疫苗
• 小分子

第11章 癌症药物市场（按适应症）

• 血癌
  • 白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
  • 淋巴瘤
    • 何杰金氏淋巴瘤
    • 非何杰金氏淋巴瘤
• 乳癌
• 大肠直肠癌
• 肺癌
• 摄护腺癌

第十二章 抗癌药物市场（依最终用户）

• 医院
• 研究所
• 专科诊所

第十三章 抗癌药物市场（依通路）

• 医院药房
• 网路药局
• 零售药局

第十四章 抗癌药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章 抗癌药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国抗癌药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Apres-demain SA
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Cipla Limited
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Roche Holding AG
  • Shorla Oncology
  • Sun Pharmaceutical Industries Ltd
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.

The Oncology Drugs Market is projected to grow by USD 386.41 billion at a CAGR of 7.92% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 210.00 billion
Estimated Year [2025]	USD 225.54 billion
Forecast Year [2032]	USD 386.41 billion
CAGR (%)	7.92%

Concise foundational orientation to the evolving oncology therapeutic arena integrating scientific innovation, delivery modalities, and stakeholder implications for strategy

The oncology therapeutic landscape is at an inflection point shaped by converging clinical advances, shifting care delivery, and heightened supply chain sensitivity. This introduction frames the critical forces driving decision-making for developers, investors, clinicians, and payers, and sets the tone for strategic action. Over recent years, therapeutic innovation has broadened beyond traditional cytotoxic agents into a heterogeneous set of approaches that include hormonal therapies, an expanding immunotherapy universe, and highly selective targeted agents. Within chemotherapy, agents such as alkylating compounds and antimetabolites remain foundational for numerous regimens, while immunotherapy now spans engineered cellular platforms through CAR T-cell products and systemic immune modulators via checkpoint blockade, including CTLA-4 and PD-1/PD-L1 mechanisms. Targeted therapies continue to evolve across monoclonal antibody formats-both chimeric and humanized-and small molecule inhibitors targeting kinases and cell-cycle regulators.

In parallel, modality and delivery considerations have become strategic differentiators: injectable administrations delivered intravenously, subcutaneously, or intramuscularly coexist with expanding oral regimens that prioritize outpatient convenience. The rise of biologics, including monoclonal antibodies and therapeutic vaccines, sits alongside small-molecule programs that emphasize oral bioavailability and intracellular targets. Indication complexity ranges from hematologic malignancies such as leukemia and lymphoma, with further subtypes including acute myeloid leukemia and chronic lymphocytic leukemia and Hodgkin and non-Hodgkin categories, to solid tumor priorities like breast, colorectal, lung, and prostate cancers. End-user dynamics involve hospitals, specialty clinics, and research institutes that each demand distinct supply, reimbursement, and clinical integration strategies, while distribution routes span hospital pharmacies, retail and online channels that influence access and adherence.

This overview underscores that successful oncology strategies must integrate scientific innovation with pragmatic planning across manufacturing, regulatory engagement, and commercial operations. The sections that follow unpack transformative shifts, tariff-related pressures, segmentation-driven priorities, regional differentiators, competitive behaviors, and actionable recommendations designed to equip leaders to navigate an increasingly complex therapeutic and commercial environment.

Assessment of the major technological, regulatory, and commercial shifts that are driving the next generation of oncology therapies and care delivery models

The last decade has seen transformative shifts that are redefining standards of care, commercial models, and investment priorities across oncology. Rapid advances in immuno-oncology have altered treatment paradigms, driven by the maturation of CAR T-cell therapies and the expansion of checkpoint inhibitors targeting CTLA-4 and PD-1/PD-L1 pathways. These modalities have not only delivered durable responses in previously refractory indications but have also reshaped expectations for long-term disease control and combination strategies. Concurrently, targeted therapy development has accelerated, with monoclonal antibodies-both chimeric and humanized-being complemented by small molecule inhibitors such as tyrosine kinase inhibitors and cyclin-dependent kinase inhibitors that enable precision targeting of oncogenic drivers.

Manufacturing innovation has followed clinical progress, with biologics production and complex cell therapy supply chains necessitating advanced cold-chain logistics, specialized contract development and manufacturing organization partnerships, and on-site capabilities for some high-touch therapies. At the same time, oral administration has gained prominence as health systems and patients seek outpatient alternatives that reduce facility burden and improve adherence. Digital therapeutics, remote monitoring, and decentralized trial models are enabling broader patient engagement and faster data capture while real-world evidence programs increasingly support reimbursement narratives.

Regulatory pathways have adapted to novel science through expedited approval mechanisms and greater reliance on surrogate endpoints and post-approval commitments, which encourages earlier commercialization but also demands robust post-market evidence generation. Commercially, payers are experimenting with outcomes-based agreements and value-based contracting, forcing manufacturers to align pricing with demonstrable clinical benefit. Altogether, these shifts compel stakeholders to pursue flexible development platforms, resilient production footprints, and integrated evidence strategies to capture the full therapeutic and economic value of emerging oncology assets.

Integrated analysis of how cumulative tariff developments through 2025 interact with supply chains, procurement strategies, and access dynamics across oncology stakeholders

Policy actions that alter cross-border trade and tariffs have material implications for complex pharmaceutical supply chains, and the cumulative effects of tariff changes announced or implemented through 2025 require careful interpretation. Tariff pressure can manifest as higher input costs for active pharmaceutical ingredients, biologics raw materials such as single-use components and cell culture media, and specialty excipients. In response, manufacturers may re-evaluate supplier portfolios and accelerate qualification of alternate vendors or contract manufacturers to mitigate concentrated exposure. Consequently, some organizations will pursue partial onshoring or nearshoring strategies to reduce tariff-induced volatility, but those moves carry capital and time costs, regulatory requalification requirements, and potential capacity constraints.

Hospitals, specialty clinics, and hospital pharmacies facing increased procurement costs may implement tighter formulary management and prioritize medications with clearer therapeutic value and procurement flexibility. Research institutes may experience budgetary displacement as procurement and operational expenses absorb tariff-related increases, potentially influencing the pace and scope of investigator-initiated studies. Distribution channels, including online and retail pharmacies, may adapt by renegotiating supplier agreements or shifting inventory strategies to maintain patient access while protecting margins.

From a development perspective, increased upstream costs can pressure R&D budgets and may change go/no-go calculus for late-stage assets with marginal therapeutic differentiation. Meanwhile, regulatory authorities are likely to scrutinize supply continuity and quality assurance as companies modify manufacturing footprints. Stakeholders should therefore pursue comprehensive supply chain visibility, scenario planning for tariff shocks, and proactive engagement with suppliers and regulators to preserve access and clinical continuity without undermining innovation incentives.

In-depth segmentation intelligence linking therapeutic classes, administration modes, molecule types, clinical indications, and channel behaviors to strategic imperatives

A segmentation-driven perspective reveals differentiated opportunities and operational imperatives across therapeutic classes, administration routes, molecule types, indications, end users, and distribution channels. Drug class segmentation underscores that traditional chemotherapy remains essential in combination regimens, with alkylating agents and antimetabolites retaining utility for certain protocols, whereas immunotherapy's subsegments-CAR T-cell therapies and checkpoint inhibitors-drive distinct manufacturing, clinical, and commercial approaches due to their personalized production and long-term efficacy profiles. The checkpoint inhibitor subset, including CTLA-4 and PD-1/PD-L1 inhibitors, emphasizes systemic immune modulation and generates unique evidence needs tied to durable response metrics. Targeted therapies bifurcate into monoclonal antibodies and small molecule inhibitors; within monoclonal antibodies, differences between chimeric and humanized formats influence immunogenicity risk profiles and manufacturing complexity, while small molecule categories such as cyclin-dependent kinase inhibitors and tyrosine kinase inhibitors carry different development and delivery advantages.

Route of administration segmentation differentiates market access and patient experience: injectable therapies delivered intravenously, subcutaneously, or intramuscularly demand infusion capacity, trained clinical staff, and robust cold-chain management, while oral formulations enable decentralized dispensing and adherence solutions. Molecule type considerations separate biologics, including monoclonal antibodies and vaccines, from small molecules, each requiring tailored manufacturing ecosystems and regulatory evidence packages. Indication-based segmentation highlights that hematologic malignancies like leukemia and lymphoma, with subtypes such as acute myeloid leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma, create concentrated needs for cellular therapies and novel combination strategies, while solid tumors such as breast, colorectal, lung, and prostate cancers drive broad population-level considerations for screening, biomarker development, and long-term survivorship care. End-user segmentation emphasizes differentiated procurement and adoption dynamics across hospitals, research institutes, and specialty clinics. Finally, distribution channel distinctions among hospital pharmacies, online pharmacies, and retail pharmacies determine how therapies are stocked, reimbursed, and accessed, directly impacting adherence and downstream outcomes. Synthesizing these segmentation layers supports targeted portfolio prioritization, supply chain design, and evidence generation activities that align with clinical and commercial realities.

Geographic differentiation and actionable regional intelligence that align regulatory realities, manufacturing capacity, and payer environments to access strategies

Regional dynamics profoundly shape development priorities, reimbursement pathways, and access strategies across the global oncology ecosystem. In the Americas, a combination of advanced clinical infrastructure, deep payer-commercial engagement, and concentrated biopharmaceutical investment fosters rapid uptake of high-cost innovative therapies, especially in hematologic malignancies and precision-targeted indications. Regulatory and reimbursement discussions in this region increasingly hinge on real-world outcomes and value-based arrangements that influence launch sequencing and commercial access plans. Europe, Middle East & Africa feature varied regulatory environments and diverse payer capacities, prompting differentiated market entry strategies. Western European health systems often emphasize health technology assessment-driven evaluations and pricing negotiations, while regional pockets in the Middle East and Africa confront infrastructure and capacity limitations that affect adoption timelines for complex biologics and cell therapies. Manufacturers must therefore tailor access models, local partnerships, and capacity-building initiatives that address country-specific reimbursement and delivery constraints. Asia-Pacific encompasses highly dynamic markets with substantial manufacturing capacity, a rapidly growing clinical trial footprint, and evolving reimbursement landscapes. Several countries in this region are investing in domestic biologics and small-molecule production, which creates both competitive pressures and partnership opportunities for global developers. Across all regions, localization of clinical evidence, engagement with regional opinion leaders, and supply chain resiliency are critical for sustaining launches and scaling patient access, with each geography demanding bespoke regulatory and commercial strategies that reflect its health system architecture and patient population needs.

Strategic behaviors and capability development among leading biopharma, biotech, and manufacturing partners that define competitive advantage in oncology

Company behavior in oncology reflects a broad spectrum of strategic responses to scientific opportunity and operational complexity. Large integrated pharmaceutical organizations are prioritizing portfolio diversification that balances innovative biologics and cell therapies with incremental improvements in small molecule franchises, leveraging scale to invest in manufacturing capacity and global commercial networks. Emerging biotechs often pursue focused indications where mechanism-of-action clarity and biomarker-driven patient selection can drive differentiation, while companies developing cell therapies concentrate on building specialized manufacturing capabilities and partnerships for decentralized delivery. Contract development and manufacturing organizations are expanding capabilities for both biologics and complex cell therapy workflows, positioning themselves as essential partners for sponsors seeking to mitigate capital intensity and accelerate capacity ramp-up.

Across these company types, common strategic behaviors include pursuing strategic alliances, licensing arrangements, and selective M&A to fill capability gaps-particularly in areas such as gene editing, cell therapy automation, and advanced analytics. Firms are also investing in evidence-generation platforms that integrate clinical trial data with real-world outcomes to support payer negotiations and value-based contracting. Operationally, companies are strengthening supply chain visibility and dual-source strategies to reduce exposure to tariff-driven cost volatility and to ensure continuity for temperature-sensitive biologics. Competitive differentiation increasingly depends on the ability to demonstrate long-term clinical benefit, manage complex logistics, and present credible pricing and access plans aligned to diverse payer requirements.

Pragmatic and prioritized recommendations for executives to strengthen supply continuity, evidence generation, and commercial readiness for oncology portfolios

Industry leaders must execute a set of coordinated actions to convert scientific progress into sustainable commercial and clinical impact. First, prioritizing supply chain resilience through multi-sourcing, inventory optimization, and strategic onshoring where feasible will mitigate exposure to tariff-driven cost shocks and ensure stability for temperature-sensitive biologics and cell therapies. Second, aligning clinical development with payer evidence expectations by embedding real-world evidence strategies and health economics endpoints early in development will enhance reimbursement readiness and reduce launch friction. Third, investing in manufacturing partnerships and modular production technologies-particularly for complex biologics and CAR T platforms-can accelerate scale-up while managing capital outlay.

Fourth, designing flexible commercialization models that accommodate both hospital-administered and outpatient oral therapies will improve patient access and facilitate care transitions. Fifth, pursuing strategic collaborations that combine diagnostic and therapeutic capabilities will strengthen biomarker-driven positioning and enable targeted indications. Sixth, adopting digital and decentralized clinical trial methodologies will broaden patient recruitment, accelerate data collection, and support post-approval evidence generation. Seventh, negotiating innovative contracting arrangements with payers, including outcome-based agreements, will align pricing with clinical performance and de-risk uptake for high-cost therapies. Finally, fostering cross-functional alignment between R&D, regulatory, manufacturing, and commercial teams will ensure faster decision cycles and coherent market entry strategies. Taken together, these recommendations provide a pragmatic roadmap for organizations seeking to sustain innovation while navigating cost pressures and access barriers.

Transparent multi-method research approach combining stakeholder interviews, literature synthesis, and data triangulation to validate oncology insights and assumptions

This research integrates primary and secondary methodologies designed to deliver rigorous, validated insights. Primary research incorporated structured interviews with a cross-section of stakeholders including clinical investigators, hospital pharmacists, payers, specialty clinic directors, and executives from biopharma and contract manufacturing organizations. These interviews were used to capture operational realities, procurement behaviors, and evidence expectations from multiple vantage points. Secondary research involved a systematic review of peer-reviewed literature, regulatory guidance documents, public filings, conference proceedings, and technical white papers to construct a comprehensive evidence base. Data triangulation techniques reconciled insights across sources, and findings were cross-validated through follow-up expert consultations to ensure consistency and to resolve divergent perspectives.

Segment mapping was applied to align therapeutic classes, administration routes, molecule types, indications, end users, and distribution channels with observed adoption patterns and operational constraints. Quality assurance steps included methodological peer review, source traceability, and sensitivity analysis to identify areas of higher uncertainty. Limitations of the approach are acknowledged: stakeholder interviews reflect current practices and perceptions that can evolve rapidly, and public documentation may lag behind fast-moving innovations. To manage these constraints, the study emphasizes transparent assumptions and specific evidence citations for key conclusions, and it recommends that users complement this work with targeted primary engagements tailored to their strategic questions. Ethical standards and confidentiality protocols governed all primary interactions, and proprietary information shared by participants was treated in accordance with agreed confidentiality provisions.

Conclusive synthesis emphasizing the convergence of innovation, operational readiness, and policy considerations that determine long-term oncology impact

The synthesis of scientific innovation, operational complexity, and policy dynamics presented here highlights that oncology stakeholders must be both agile and deliberate. Advancements in immunotherapy and targeted agents offer meaningful clinical promise, but realizing that promise at scale requires integrated strategies spanning manufacturing resilience, evidence generation, and adaptive commercialization. Tariff and trade developments through 2025 add a layer of operational risk that can affect input costs, procurement behavior, and access pathways, making supply chain visibility and scenario planning essential priorities.

Segmentation and regional analyses demonstrate that therapeutic, delivery, and geographic nuances demand tailored approaches rather than one-size-fits-all plans. Companies that invest in modular manufacturing, smart partnerships, and early payer engagement will be better positioned to navigate reimbursement complexity and to secure durable adoption for innovative treatments. Meanwhile, health systems and payers benefit from clearer outcome data and collaboration models that align cost with long-term patient benefit. In closing, the current environment rewards organizations that combine scientific rigor with operational foresight; stakeholders who integrate these dimensions into strategy development will be best placed to convert therapeutic breakthroughs into sustained clinical and commercial success.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rapid adoption of personalized neoantigen vaccine platforms targeting tumor-specific mutations in solid cancers
• 5.2. Growing integration of ultra-sensitive liquid biopsy assays for minimal residual disease monitoring in hematologic malignancies
• 5.3. Expansion of CD19-targeted CAR T cell therapies into earlier lines of diffuse large B cell lymphoma treatment protocols
• 5.4. Emergence of next generation KRAS G12C and G12D inhibitors demonstrating durable responses across lung and colorectal cancers
• 5.5. Increasing partnerships between pharmaceutical companies and diagnostic developers for PD-L1 companion diagnostic co-development programs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Drugs Market, by Drug Class

• 8.1. Chemotherapy Agents
  • 8.1.1. Alkylating Agents
  • 8.1.2. Antimetabolites
• 8.2. Hormonal Therapy Agents
• 8.3. Immunotherapy Agents
  • 8.3.1. CAR T-Cell Therapy
  • 8.3.2. Checkpoint Inhibitors
    • 8.3.2.1. CTLA-4 Inhibitors
    • 8.3.2.2. PD-1/PD-L1 Inhibitors
• 8.4. Targeted Therapy Agents
  • 8.4.1. Monoclonal Antibodies
    • 8.4.1.1. Chimeric
    • 8.4.1.2. Humanized
  • 8.4.2. Small Molecule Inhibitors
    • 8.4.2.1. Cyclin-Dependent Kinase Inhibitors
    • 8.4.2.2. Tyrosine Kinase Inhibitors

9. Oncology Drugs Market, by Route of Administration

• 9.1. Injectable
  • 9.1.1. Intramuscular
  • 9.1.2. Intravenous
  • 9.1.3. Subcutaneous
• 9.2. Oral

10. Oncology Drugs Market, by Molecule Type

• 10.1. Biologics
  • 10.1.1. Monoclonal Antibodies
  • 10.1.2. Vaccines
• 10.2. Small Molecules

11. Oncology Drugs Market, by Indication

• 11.1. Blood Cancer
  • 11.1.1. Leukemia
    • 11.1.1.1. Acute Myeloid Leukemia
    • 11.1.1.2. Chronic Lymphocytic Leukemia
  • 11.1.2. Lymphoma
    • 11.1.2.1. Hodgkin Lymphoma
    • 11.1.2.2. Non-Hodgkin Lymphoma
• 11.2. Breast Cancer
• 11.3. Colorectal Cancer
• 11.4. Lung Cancer
• 11.5. Prostate Cancer

12. Oncology Drugs Market, by End User

• 12.1. Hospitals
• 12.2. Research Institutes
• 12.3. Specialty Clinics

13. Oncology Drugs Market, by Distribution Channel

• 13.1. Hospital Pharmacies
• 13.2. Online Pharmacies
• 13.3. Retail Pharmacies

14. Oncology Drugs Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Oncology Drugs Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Oncology Drugs Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. AbbVie Inc.
  • 17.3.2. Agenus Inc.
  • 17.3.3. Amgen Inc.
  • 17.3.4. Apres-demain SA
  • 17.3.5. Aspen Pharmacare Holdings Limited
  • 17.3.6. Astellas Pharma Inc.
  • 17.3.7. AstraZeneca PLC
  • 17.3.8. Bayer AG
  • 17.3.9. BeiGene, Inc.
  • 17.3.10. Bristol-Myers Squibb Company
  • 17.3.11. C.H. Boehringer Sohn AG & Co. KG
  • 17.3.12. Cipla Limited
  • 17.3.13. Eli Lilly and Company
  • 17.3.14. GSK plc
  • 17.3.15. Johnson & Johnson Services, Inc.
  • 17.3.16. Merck KGaA
  • 17.3.17. Pfizer Inc.
  • 17.3.18. Puma Biotechnology, Inc.
  • 17.3.19. Roche Holding AG
  • 17.3.20. Shorla Oncology
  • 17.3.21. Sun Pharmaceutical Industries Ltd
  • 17.3.22. Sutro Biopharma, Inc.
  • 17.3.23. Takeda Pharmaceutical Company Limited
  • 17.3.24. Viatris Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HORMONAL THERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PD-1/PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CYCLIN-DEPENDENT KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 279. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 280. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 283. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 286. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 289. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 290. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 291. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 292. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 293. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 294. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 295. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 296. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 297. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2018-2024 (USD MILLION)
• TABLE 298. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2025-2032 (USD MILLION)
• TABLE 299. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2018-2024 (USD MILLION)
• TABLE 300. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2025-2032 (USD MILLION)
• TABLE 301. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 302. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 303. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2018-2024 (USD MILLION)
• TABLE 304. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2025-2032 (USD MILLION)
• TABLE 305. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 306. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 307. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 308. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 309. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 310. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 311. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 312. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 313. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 314. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 315. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 316. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 317. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 318. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 319. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
• TABLE 320. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2032 (USD MILLION)
• TABLE 321. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 322. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 323. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 324. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 325. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 326. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 327. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 328. AMERICAS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 329. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 330. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 331. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)

TABLE 3